The drug contains the active ingredient tirzepatide, which originally approved in 2022 to treat type 2 diabetes under the name Mounjaro
Actualmente, Mounjaro solo es adecuado para pacientes mayores de 18 aos, ya que su efecto en personas ms jvenes an no se ha estudiado
Resistance training remains the foundation
Injection Sites for Tirzepatide The injection sites for tirzepatide are identical to those mentioned above: abdomen, thigh, or upper arm
Sergey Terushkin, MD, FACS Key Takeaways Tirzepatide, marketed as Mounjaro, was initially developed for type 2 diabetes but has rapidly emerged as one of the most effective medications for medical weight loss
Hindering Glucagon production